Navigation Links
Surveyed European Oncologists Assign Greater Patient Share to Johnson & Johnson's Abiraterone Compared With Other Emerging Therapies in Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Date:9/30/2010

BURLINGTON, Mass., Sept. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, according to surveyed European oncologists, Johnson & Johnson's abiraterone will capture greater patient share than Dendreon's Provenge, AstraZeneca's zibotentan or Bristol-Myers Squibb's ipilimumab in asymptomatic or minimally symptomatic, metastatic castrate-resistant prostate cancer (MCRPC).

According to the new European Physician & Payer Forum report entitled Will Emerging Agents for Prostate Cancer Achieve Acceptance from Payers and Prescribers in Europe?, surveyed oncologists in France, Germany, Italy, Spain and the United Kingdom say that efficacy is overwhelmingly the most important factor dictating the uptake of emerging therapies for MCRPC.

"Emerging agents need to improve efficacy over current standards of care in order to penetrate the market," said Decision Resources Analyst Andrew Merron, Ph.D. "The barrier is lower in the asymptomatic MCRPC setting where clinicians are dependent on hormonal therapies, while barriers are greater in the symptomatic MCRPC setting where Sanofi-Aventis's Taxotere (docetaxel), the gold-standard, is widely prescribed. As a result, most agents in clinical trials are being used in combination with Taxotere for symptomatic MCRPC."

In symptomatic MCRPC, the majority of patients will receive a Taxotere-containing regimen one year following the launch of emerging therapies. Celgene's Revlimid and Bristol-Myers Squibb's Sprycel and zibotentan will compete to partner with Taxotere. After considering reimbursement hurdles in their countries, overall, French and Italian oncologists assign the greatest patient share to Sprycel and zibotentan. However, the greatest patient share of any regimen will be attributed to Taxotere/prednisone alone with no emerging therapy additions.

In non-metastatic castrate-resis
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
2. Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
3. Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections
4. Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roches Actemra for Rheumatoid Arthritis
5. Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer
6. Majority of Surveyed Pharmacy Directors Expect To Cover Pfizers Tanezumab If It Is Approved for the Treatment of Chronic Pain
7. An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists
8. In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Nearly Half Will Use CDA1/CDB1
9. For Treatment of Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabTheras Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
10. For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Advanced Wound Dressings - SA Analysis and ... steadily replaced traditional bandages and gauze materials in ... such as trauma wounds, burns, and chronic ulcerations. ... become increasingly critical in wound healing, advanced dressings ... This report focuses on nine market categories within ...
(Date:9/2/2015)... , Sept. 2, 2015 About Neuroendovascular ... used to treat an unruptured and ruptured brain ... The treatment is either known as an endovascular ... endovascular coil blocks the blood flow in an ... under general anaesthesia by an interventional neuroradiologist using ...
(Date:9/2/2015)... , Sept. 2, 2015 Advanced Wound ... Summary Advanced dressings have steadily replaced traditional ... a variety of wound indications, such as trauma ... infection control, and physical protection become increasingly critical ... role in standard therapy. This report focuses ...
Breaking Medicine Technology:Advanced Wound Dressings - SA Analysis and Market Forecasts 2Global Neuroendovascular Coil Market 2015-2019 2Advanced Wound Dressings - 5EU Analysis and Market Forecasts 2
... April 03, 2007,/PRNewswire-FirstCall/ -- Cell Genesys, Inc. ... multi-center Phase 2 trial of GVAX,immunotherapy for ... immunotherapy in 80 patients with metastatic,hormone-refractory prostate ... who received the dose that is comparable ...
... for the Study,of the Liver, PRINCETON, N.J., April 03, ... studies of,Clevudine for the treatment of hepatitis B (HBV) ... of hepatitis C (HCV),will be made during the 42nd ... the Liver (EASL) being held in,Barcelona, Spain from April ...
Cached Medicine Technology:Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 2Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 3Pharmasset Announces Clevudine and Hepatitis C Presentations at,EASL 2Pharmasset Announces Clevudine and Hepatitis C Presentations at,EASL 3Pharmasset Announces Clevudine and Hepatitis C Presentations at,EASL 4
(Date:9/2/2015)... ... September 02, 2015 , ... On ... Officers Association of America (MOAA) and Wounded Warrior Project® (WWP), will be ... Own,” expert panelists will lead interactive discussions on the responsibilities and commitments ...
(Date:9/2/2015)... ... , ... Telehealth represents a growing trend among Blue Cross and Blue Shield ... more than 12 Blues plan clients. The September 2015 issue of The ... trend, interviewing executives at Capital Blue Cross, whose telehealth services will launch next year. ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... In “Failure ... by the Huffington Post on August 25th, writer Akela Stanfield detailed her lifelong struggle ... the author acknowledged that she had always seen herself as someone who would lose ...
(Date:9/2/2015)... ... 02, 2015 , ... Splashtop Inc., the worldwide leader in ... mirroring and extending product line -- Splashtop Wired XDisplay . Complementing ... setting, the new Splashtop Wired XDisplay delivers enhanced performance and reliability for users ...
(Date:9/2/2015)... ... ... Good health and a good cause paired up at The Barclays this past ... to the New Jersey Golf Foundation through its Healthy Steps Challenge. After making ... BCBSNJ challenged PGA TOUR golfer and NJ native Morgan Hoffmann to add more by ...
Breaking Medicine News(10 mins):Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 3Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:Recent Editorial on Bariatric Surgery Acceptance Illuminates a Typical Journey Towards Weight Loss Surgery, Notes Dr. Michael Feiz 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 3Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 3
... to warn Indonesians about bird flu will commence next week,. ... of 49 people in the country which ranks as ... to John Budd, head of communications with the United Nations ... several members of socio- religious groups will be involved in ...
... and vitamin D supplements is apparently of no use in ... //from the Women's Health Initiative study. Previous research had suggested ... risk. ,'We can't yet make a general recommendation ... each day as supplements,' said Dr. Rowan Chlebowski, the study's ...
... 200 elderly people in the Argyll and Bute Council area ... it has emerged//. Labour MSP Jackie Baillie said that the ... investigate. ,Argyll and Bute Council said it had ... that there were about 200 eligible people not receiving care, ...
... major Ranbaxy Laboratories Ltd today said its wholly owned ... //with Hyderabad-based Zenotech Laboratories Ltd to market generic cancer ... the agreement, Zenotech Labs would develop, submit for regulatory ... Ranbaxy would market these products as generic formulations in ...
... Togadiya, who underwent an angioplasty at a private hospital here, ... ,Togadiya was admitted to SAL hospital here yesterday, ... Bhupesh Shah carried out the angioplasty on Togadiya last night., ... of the leader is stable and he is expected to ...
... beer while watching the World Cup on television may be ... the game, says a new study. // ,Psychology ... are not confident of their sporting abilities are likely to ... ,The study, based on interviews with 31 London youths in ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: